{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:56:09Z","timestamp":1778777769496,"version":"3.51.4"},"reference-count":35,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2000,9,1]],"date-time":"2000-09-01T00:00:00Z","timestamp":967766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cardiovasc Pharmacol Ther"],"published-print":{"date-parts":[[2000,9]]},"abstract":"<jats:p>Background: Heart-rate (HR) variability is an important predictor of mortality in patients with heart disease. We examined the effects of cilostazol, a quinolinone derivative, on HR and HR variability in patients with chronic atrial fibrillation associated with bradycardia episodes.<\/jats:p>\n                  <jats:p>Patients and Methods: Thirteen patients with chronic atrial fibrillation associated with bra dycardia episodes (minimal HR &lt;40\/min and\/or pauses, ie, episodes with an RR interval &gt; 2.5 sec) received cilostazol (100 or 200 mg\/day) orally for at least 2 months and 24-hour Holter electrocardiography was performed before and after the start of cilostazol administration.<\/jats:p>\n                  <jats:p>Results: Minimal HR was significantly increased, by an average of 14 beats\/min (bpm), at 3.3 \u00b1 0.8 weeks (mean \u00b1 SD) after the start of cilostazol treatment. The number of pauses was significantly decreased. As a consequence, mean HR was increased by an average of 18 bpm. Maximal HR was also increased by an average of 19 bpm. The circadian variation of the HR, determined by cosine fitting, was not changed by cilostazol treatment. The time-domain HR variabilities, ie, the SD of the mean RR interval and the SD of the 5-minute mean RR intervals, were also unchanged. New York Heart Association functional class was signifi cantly improved and the plasma atrial natriuretic polypeptide level was significantly de creased after the initiation of cilostazol treatment.<\/jats:p>\n                  <jats:p>Conclusion: Cilostazol improves the slow HR episodes associated with chronic atrial fibril lation and maintains the HR circadian variation and time-domain variability, indicating that cilostazol has therapeutic utility for the treatment of the slow HR associated with chronic atrial fibrillation.<\/jats:p>","DOI":"10.1054\/jcpt.2000.8696","type":"journal-article","created":{"date-parts":[[2008,7,22]],"date-time":"2008-07-22T12:00:14Z","timestamp":1216728014000},"page":"183-191","source":"Crossref","is-referenced-by-count":24,"title":["Effects of Cilostazol on Heart Rate and its Variation in Patients With Atrial Fibrillation Associated With Bradycardia"],"prefix":"10.1177","volume":"5","author":[{"given":"Shinji","family":"Toyonaga","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, Faculty of Medicine, Okayama University Medical School, Cardiovascular Division, Yashima General Hospital, Kagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Nakatsu","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Yashima General Hospital, Kagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Medical Technology, Faculty of Health Sciences, Okayama University Medical School, Okayama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shozo","family":"Kusachi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Faculty of Medicine, Okayama University Medical School, Department of Medical Technology, Faculty of Health Sciences, Okayama University Medical School, Okayama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Mashima","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Yashima General Hospital, Kagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youkou","family":"Tominaga","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Yashima General Hospital, Kagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Yamane","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Yashima General Hospital, Kagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadahisa","family":"Uesugi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Faculty of Medicine, Okayama University Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Kanai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Faculty of Medicine, Okayama University Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Faculty of Medicine, Okayama University Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2000,9,1]]},"reference":[{"key":"atypb1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.63.3.157"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-1-1"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(90)90942-T"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(90)90552-Z"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(84)90103-5"},{"key":"atypb6","first-page":"1201","volume":"35","author":"Kamiya T.","year":"1985","journal-title":"Arzneimittelforschung"},{"key":"atypb7","first-page":"1154","volume":"35","author":"Kawamura K.","year":"1985","journal-title":"Arzneimittelforschung"},{"key":"atypb8","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0026-895X(25)10404-5","volume":"30","author":"Kauffman RF","year":"1986","journal-title":"Mol Pharmacol"},{"key":"atypb9","first-page":"551","volume":"10","author":"Weishaar RE","year":"1985","journal-title":"J Cyclic Nucleotide Protein Phosphorylation Res"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(89)90391-3"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199804000-00010"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1097\/00001573-199801000-00006"},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(95)90043-8"},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(94)90584-3"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.88.1.127"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540350075038"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/8.3.347"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1016\/0022-0736(90)90163-V"},{"key":"atypb19","unstructured":"Feigenbaum H. Echocardiographic findings with altered electrical activation. In Feigenbaum H (ed.) Echocardiography. Lea & Ferbiger, Philadelphia, pp. 216-238, 1994"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.1860060407"},{"key":"atypb21","first-page":"1133","volume":"35","author":"Akiyama H.","year":"1985","journal-title":"Arzneimittelforschung"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.1016\/0300-9572(80)90007-6"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-0736(73)80006-8"},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91517-E"},{"key":"atypb25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199111213252103"},{"key":"atypb26","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199810000-00012"},{"key":"atypb27","first-page":"327","volume":"10","author":"Wolk R.","year":"1996","journal-title":"J Hum Hypertens"},{"key":"atypb28","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199610000-00006"},{"key":"atypb29","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199424020-00011"},{"key":"atypb30","first-page":"17","volume":"1","author":"Tsutamoto T.","year":"1989","journal-title":"Am Heart J"},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113544"},{"key":"atypb32","first-page":"72","volume":"15","author":"Alboni P.","year":"1993","journal-title":"Am J Cardiol"},{"key":"atypb33","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(92)90991-7"},{"key":"atypb34","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90352-D"},{"key":"atypb35","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00737-1"}],"container-title":["Journal of Cardiovascular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1054\/JCPT.2000.8696","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1054\/JCPT.2000.8696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:40:52Z","timestamp":1777394452000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1054\/JCPT.2000.8696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,9]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,9]]}},"alternative-id":["10.1054\/JCPT.2000.8696"],"URL":"https:\/\/doi.org\/10.1054\/jcpt.2000.8696","relation":{},"ISSN":["1074-2484","1940-4034"],"issn-type":[{"value":"1074-2484","type":"print"},{"value":"1940-4034","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,9]]}}}